ADA 2018

ADA: T1D, T2D, GDM Before 26 Weeks Tied to Higher ASD Risk

ADA: T1D, T2D, GDM Before 26 Weeks Tied to Higher ASD Risk

Study shows increased risks of autism spectrum disorder in association with types 1, 2, gestational diabetes.

Cardiovascular Outcomes in Patients With ACS, Diabetes Using Alirocumab

Cardiovascular Outcomes in Patients With ACS, Diabetes Using Alirocumab

By

Investigators examine the effects of the PCSK9 inhibitor alirocumab in patients with recent acute coronary syndrome and diabetes.

Dual-Hormone Artificial Pancreas Reduces Glucose Variability in T1D

Dual-Hormone Artificial Pancreas Reduces Glucose Variability in T1D

By

Investigators conducted a randomized crossover comparison of 2 dual-hormone artificial pancreas systems — one with rapid insulin and amylin, and another with regular insulin and amylin — with a rapid insulin-alone artificial pancreas.

Improved Glycemic Control With Closed-Loop Insulin Delivery System

Improved Glycemic Control With Closed-Loop Insulin Delivery System

By

Researchers conducted a randomized, open-label trial to assess the effect of an automated closed-loop insulin delivery system on glycemic control in hospitalized patients.

Technosphere Inhaled Insulin Improves Glycemic Control in Type 1 Diabetes

Technosphere Inhaled Insulin Improves Glycemic Control in Type 1 Diabetes

By

Patients were randomly assigned to receive insulin aspart or Technosphere inhaled insulin.

Safety and Performance of Omnipod HCL for Children With Type 1 Diabetes

Safety and Performance of Omnipod HCL for Children With Type 1 Diabetes

By

In children with type 1 diabetes, the Omnipod hybrid closed-loop personal model system was safe and performed well.

Pen vs Patch Bolus Insulin Delivery for T2D Using CGM

Pen vs Patch Bolus Insulin Delivery for T2D Using CGM

By

Investigators compared 2 methods of delivering bolus insulin, pen vs patch, using metrics from continuous glucose monitoring.

Empagliflozin, Liraglutide Reduce Cardiovascular Mortality Risk

Empagliflozin, Liraglutide Reduce Cardiovascular Mortality Risk

By

Investigators conducted a meta-analysis to compare the efficacy of SGLT2i, DPP-4i, and GLP-1 agonists for reducing cardiovascular outcomes.

Type 2 Diabetes Does Not Affect Pneumonia Incidence, Outcomes After Stroke

Type 2 Diabetes Does Not Affect Pneumonia Incidence, Outcomes After Stroke

By

Investigators examined the incidence and outcomes of pneumonia in patients with acute ischemic stroke and type 2 diabetes.

Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents

Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents

Investigators analyzed real world data to examine the risk for below-knee amputations in patients with type 2 diabetes taking canagliflozin vs other medications.

Beta-Blockers Show Varied Effects on Hypoglycemic Mortality Risk in Diabetes

Beta-Blockers Show Varied Effects on Hypoglycemic Mortality Risk in Diabetes

Investigators examined the relationship between the use of β-blockers and incidence of hypoglycemia and risk for mortality in hospitalized patients with diabetes.

Metabolic Health Predicative of Cognitive Development in Children

Metabolic Health Predicative of Cognitive Development in Children

By

Researchers assessed whether current metabolic parameters are inversely associated with cognitive functioning.

Long-Term Sotagliflozin Safe, Effective as Adjunct Therapy to Insulin in Type 1 Diabetes

Long-Term Sotagliflozin Safe, Effective as Adjunct Therapy to Insulin in Type 1 Diabetes

By

After insulin optimization, participants with type 1 diabetes were randomly assigned to placebo, sotagliflozin 200 mg, or sotagliflozin 400 mg with insulin.

ITCA 650 Shows Efficacy in Reducing Weight, HbA1c in Type 2 Diabetes

ITCA 650 Shows Efficacy in Reducing Weight, HbA1c in Type 2 Diabetes

By

The ITCA 650, a small titanium osmotic mini-pump, provides a subcutaneous infusion of exenatide over 3 or 6 months.

Exenatide, Basal Insulin Combination Effective for Inpatient Treatment of Diabetes

Exenatide, Basal Insulin Combination Effective for Inpatient Treatment of Diabetes

By

The safety and efficacy of exenatide alone or in combination with basal insulin in surgery and medicine patients with type 2 diabetes examined.

MEDI0382 Safe, Effective for Normalizing Glucose, Weight Loss in Type 2 Diabetes

MEDI0382 Safe, Effective for Normalizing Glucose, Weight Loss in Type 2 Diabetes

By

MEDI0382 reduced body weight and normalized fasting and postprandial blood glucose levels in patients with type 2 diabetes.

Liraglutide May Prevent Dementia in Elderly With Type 2 Diabetes

Liraglutide May Prevent Dementia in Elderly With Type 2 Diabetes

By

Investigators examined the efficacy of liraglutide for the prevention of dementia in elderly patients with type 2 diabetes.

Semaglutide vs Dulaglutide for HbA1c, Body Weight Reduction in T2D

Semaglutide vs Dulaglutide for HbA1c, Body Weight Reduction in T2D

By

Semaglutide was associated with HbA1c and body weight reductions compared with patients taking dulaglutide.

High-Intensity Statins Do Not Worsen Glucose Homeostasis in Type 2 Diabetes

High-Intensity Statins Do Not Worsen Glucose Homeostasis in Type 2 Diabetes

By

The effect of high-intensity statins compared with low-intensity statins on glycemic control was examined.

Age, Baseline HbA1c May Predict Glycemic Control in Newly Diagnosed Type 2 Diabetes

Age, Baseline HbA1c May Predict Glycemic Control in Newly Diagnosed Type 2 Diabetes

By

Investigators examined the effectiveness of oral agents vs insulin as an initial treatment option for people newly diagnosed with type 2 diabetes.

Exenatide Shows Efficacy in Improving Renal Outcomes in T2D

Exenatide Shows Efficacy in Improving Renal Outcomes in T2D

By

Investigators examined the effect of exenatide on estimated glomerular filtration rate, new macroalbuminuria, and 2 renal composites.

Empagliflozin Reduces Risk for Nephropathy Regardless of Blood Pressure, LDL Cholesterol, HbA1c

Empagliflozin Reduces Risk for Nephropathy Regardless of Blood Pressure, LDL Cholesterol, HbA1c

By

Investigators examined renal outcomes when controlling cardiovascular risk factors, such as blood pressure, LDL-C, and HbA1c.

Continuous Glucose Monitoring Controls Hypoglycemia Better Than Glucometer

Continuous Glucose Monitoring Controls Hypoglycemia Better Than Glucometer

By

Participants completed surveys for fear of hypoglycemia, hypoglycemia unawareness, and problem areas in diabetes questionnaire.

Chronic Kidney Disease More Common in Type 2 Diabetes Than in Type 1 Diabetes

Chronic Kidney Disease More Common in Type 2 Diabetes Than in Type 1 Diabetes

By

Investigators examined the prevalence of chronic kidney disease in adults with type 1 diabetes compared with type 2 diabetes.

Elevated Triglycerides, Diabetes May Be Predictors of Major Cardiovascular Events

Elevated Triglycerides, Diabetes May Be Predictors of Major Cardiovascular Events

By

Investigators examined cardiovascular outcomes in patients with elevated triglyceridemia and diabetes treated with statins.

Preventing Hypoglycemia During Exercise in Type 1 Diabetes on CSII

Preventing Hypoglycemia During Exercise in Type 1 Diabetes on CSII

By

Reducing basal insulin delivery by 50%-80% 90 minutes before aerobic exercise better prevents hypoglycemia risk vs basal suspension or disconnection at exercise onset.

Implantable Continuous Glucose Monitoring Device Safe, Effective for Adolescents

Implantable Continuous Glucose Monitoring Device Safe, Effective for Adolescents

By

The safety assessment included incidence of insertion or procedure-related removal and device-related serious adverse events through 180 after insertion.

Sign Up for Free e-Newsletters



CME Focus